Yingfei Fan "Settled" in Xinhua Pharmacy
Release time:
2020-07-15
The number of designated charity drug donation varieties in Jinqu region has reached 16
. Recently, the first PD-L1 immunotherapy drug duvalizumab (Yingfeifan) approved for listing in China has officially started to be sold. Xinhua Pharmacy, the peak pharmacy, has become the only designated pharmacy in Yingfeifan in Jinqu region and is also the designated service point for charity drug donation in Yingfeifan. On March 27, Xinhua Pharmacy completed the first sale of Yingfeifan, which was delivered to patients by licensed pharmacists in the pharmacy.
Infeifan was formally approved by the National Drug Administration (NMPA) in December 2019 for the treatment of patients with unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after receiving platinum-based chemotherapy and concurrent radiotherapy. The results of phase III PACIFIC clinical trials show that the use of Imfinzi immunotherapy after concurrent radiotherapy and chemotherapy reduces the risk of death by nearly 32% in patients with stage III inoperable NSCLC. The median progression-free survival (PFS) is 16.8 months, and the 3-year overall survival rate (OS) is as high as 57%. Infineon is the first PD-L1 immunosuppressant approved for the treatment of stage III lung cancer in mainland China. The approval marks a new era of immunotherapy for unresectable stage III non-small cell lung cancer in China.
In order to improve the accessibility and standardization of lung cancer immunotherapy for lung cancer patients, reduce the economic burden of patients and prolong the life of patients. The China Primary Health Care Foundation officially launched the "Aifan-Lung Cancer Immunotherapy Patient Assistance Project" on February 29. Patients with low-income insurance who meet the indications for the treatment of duvalizumab can receive free charity drugs until the disease progresses. In the first round, patients can get 2 courses of drug assistance free of charge after using 2 courses of duvalizumab at their own expense; in the second round, patients can get 4 courses of drug assistance free of charge after using 4 courses of duvalizumab at their own expense; in the third round, patients can get 8 courses of free drug assistance after using 6 courses of duvalizumab at their own expense, under the premise that the disease does not progress, the subsequent application for drug donation can be circulated. After investigation and evaluation in various aspects, Xinhua Pharmacy has become a designated service point for charity drug donation in Yingfeifan in Jinliqu area.
Xinhua Pharmacy is a designated pharmacy for serious illness medical insurance in Jinhua City, with complete drug equipment. All hardware facilities are perfect. For drugs that need to be refrigerated, pharmacies have special refrigerators for storage. The refrigerators are equipped with monitoring probes, which are connected to the mobile phone system. If the temperature is abnormal, SMS alarm will be issued. At the same time, Xinhua Pharmacy is also equipped with special personnel to provide drug donation services, which have previously been identified as designated service points for charity drug donation of many varieties such as Terrisa, Iressa, Gnico, Herceptin and Libitai. After Yingfeifan "settled down", there are 16 varieties of designated charity drugs in Jinqu area of Xinhua drugstore. (Reporter Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page